Sorteer per
Keyphrases
Chemotherapy
100%
Small Molecule Screen
100%
Medulloblastoma
100%
Cell Cycle Checkpoint
100%
Checkpoint Kinase Inhibitor
100%
Checkpoint Kinase 1 (CHK1)
83%
DNA Damage
33%
Radiotherapy
16%
Clinical Prognosis
16%
Tumor Protein p53 (TP53)
16%
Clinical Features
16%
Cisplatin
16%
New Therapies
16%
Cell Cycle Arrest
16%
Apoptosis
16%
Cyclophosphamide
16%
Chemotherapy-induced
16%
Clinical Evaluation
16%
Gemcitabine
16%
Improved Survival
16%
Medulloblastoma Subgroups
16%
Effective Compounds
16%
Pediatric Medulloblastoma
16%
Cytotoxic Activity
16%
Molecular Subgroups
16%
Combination Treatment
16%
Preclinical Assessment
16%
Cultured Cells
16%
Chemotherapy Alone
16%
Clinical Investigation
16%
Tumor Burden
16%
Chemosensitizing Effect
16%
High-risk Medulloblastoma
16%
Pharmacodynamic Study
16%
Cytotoxic Chemotherapy
16%
Central Nervous System Penetration
16%
Best-in-class
16%
LY2606368
16%
Assessment Platform
16%
Prexasertib
16%
High-throughput Assay
16%
Biochemistry, Genetics and Molecular Biology
Kinase
100%
Phosphotransferase
100%
Small Molecule
100%
Cell Cycle Checkpoint
100%
Clinical Trial
33%
DNA Damage
33%
Cisplatin
33%
Cell Cycle Arrest
33%
Cyclophosphamide
33%
Cytotoxicity
33%
Tumor Volume
33%
Pharmacodynamics
33%
Gemcitabine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Medulloblastoma
100%
Checkpoint Kinase Inhibitor
100%
Prexasertib
22%
Clinical Trial
11%
Neoplasm
11%
Cyclophosphamide
11%
Cisplatin
11%
Pharmacodynamics
11%
Phosphotransferase
11%
Clinical Feature
11%
Gemcitabine
11%
Cytotoxic Chemotherapy
11%
Cytotoxicity
11%
Neuroscience
Medulloblastoma
100%
Kinase
100%
Cell Cycle Checkpoint
100%
Cell Line
11%
Cisplatin
11%
TP53
11%
Radiation Therapy
11%
Cyclophosphamide
11%
DNA Damage
11%
Central Nervous System
11%
Cytotoxicity
11%
Cell Cycle Arrest
11%
Gemcitabine
11%
Immunology and Microbiology
Cell Cycle Checkpoint
100%
DNA Damage
33%
Cell Cycle Arrest
33%
Cytotoxicity
33%
Medulloblastoma Cell Line
33%
Central Nervous System
33%
Cyclophosphamide
33%
Tumor Volume
33%
Pharmacodynamics
33%